Reduced organ damage accumulation in adult patients with SLE on anifrolumab plus standard of care compared to real-world external controls
Patients who received anifrolumab accumulated significantly less organ damage after 208 weeks than patients who received RW SOC. The addition of anifrolumab to SOC is effective at preventing and/or delaying organ damage in patients with moderately to severely active SLE.
Authors
- Zahi Touma (ORCID: https://orcid.org/0000-0001-5177-2076)
- Miina Waratani (ORCID: https://orcid.org/0000-0002-4648-7454)
- Eric Francis Morand (ORCID: https://orcid.org/0000-0002-9507-3338)
- Raj Tummala (ORCID: https://orcid.org/0000-0002-5506-4445)
- J. Knagenhjelm
- Ian N Bruce (ORCID: https://orcid.org/0000-0003-3047-500X)
- Shelly Chandran (ORCID: https://orcid.org/0009-0001-2410-4424)
- Kellyn F Arnold
- Richard Alan Furie (ORCID: https://orcid.org/0000-0001-6712-1585)
- Gabriel Abreu (ORCID: https://orcid.org/0000-0001-7926-2385)
- Danuta Kielar
- Eleanor Ralphs (ORCID: https://orcid.org/0000-0001-7986-8205)
- Hopin Lee (ORCID: https://orcid.org/0000-0001-5692-0314)
- Aleksandr Bedenkov
Institutions
- Hofstra University (US)
- Toronto Western Hospital (CA)
- Manchester Academic Health Science Centre (GB)
- IQVIA (United Kingdom) (GB)
- AstraZeneca (South Korea) (KR)
- Queens University (BD)
- AstraZeneca (Australia) (AU)
- AstraZeneca (France) (FR)
- AstraZeneca (Japan) (JP)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (Canada) (CA)
- Krembil Research Institute
- Monash University (AU)
Publication Details
- Journal
- Annals of the Rheumatic Diseases
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1016/j.ard.2025.01.025
- Citations
- 10
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 16.68
Funders
- AstraZeneca